ACCD Guides Q1 Well Below Analysts' Estimates, ALNY Cuts Outlook, NVCR Braces For Busy Year

Alnylam Pharmaceuticals Inc. (ALNY) has lowered its 2022 guidance range for combined net product revenues based on the first quarter results. For full year 2022 the company now expects combined net product revenues to range between $870 million and $930 million, down from its prior guidance of $900 million to $1 billion.

from RTT - Top Story https://ift.tt/BXTykau
via IFTTT